menu ☰
menu ˟

FDA committee sees Spark’s retinal dystrophy gene therapy as having favorable benefit-risk profile

12 Oct 2017
An FDA advisory committee voted unanimously that Spark Therapeutics’ Luxturna gene therapy for retinal dystrophy has an overall favorable benefit-risk profile.Sixteen members of the Cellular, Tissue, and Gene Therapies Advisory Committee voted yes ...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.